CD19 and congenital rubella syndrome: Mice treated with methyltyrosine (MTP) and atrial natriuretic peptide (ANP) prior to CD19-CAR T-cell therapy demonstrated improved survival, as these molecules abrogated the increase in catecholamine levels and protected against CRS-associated mortality, while having little effect on anti-tumor efficacy of the CAR T-cells (44).